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Abstract
Introduction: Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review
is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation
(HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy.
Methods: Systematic literature searches were performed in MEDLINE, EMBASE, and The Cochrane Library. All databases
were searched from inception to February 2010. PubMed was searched in June 2010 for a last update. In addition to
randomized and non-randomized controlled trials, case series and case reports were included to complement results from
scant data. The primary outcome was overall survival. A meta-analysis was performed using the hazard ratio as primary
effect measure, which was estimated from Cox proportional hazard models or from summary statistics of Kaplan Meier
product-limit estimations.
Results: A total of 40 studies with 287 transplant patients with metastatic RMS (age range 0 to 32 years) were included in
the assessment. We identified 3 non-randomized controlled trials. The 3-year overall survival ranged from 22% to 53% in the
transplant groups vs. 18% to 55% in the control groups. Meta-analysis on overall survival in controlled trials showed no
difference between treatments. Result of meta-analysis of pooled individual survival data of case series and case reports,
and results from uncontrolled studies with aggregate data were in the range of those from controlled data. The risk of bias
was high in all studies due to methodological flaws.
Conclusions: HDCT followed by autologous HSCT in patients with RMS remains an experimental treatment. At present, it
does not appear justifiable to use this treatment except in appropriately designed controlled trials.
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Introduction
Rhabdomyosarcomas (RMS) are rare [1] malignant diseases
that form a subgroup of soft tissue sarcomas (STS) which affect
primarily children and young adults [2]. According to Parham
2006, "Rhabdomyosarcomas constitute a unique group of soft
tissue neoplasms that share a propensity to undergo myogenesis, a
well-defined biologic process that primarily occurs during
embryonal and fetal development. As a result, these neoplasms
tend to resemble stages of muscle formation more akin to prenatal
than postnatal life" [3]. Several histologic subtypes tend to
predominate in certain age groups and the embryonal and
alveolar types are the most common [3]. In children 0 to 14 years
of age, RMS constitute 50% of STS with an incidence rate of 4.6
per 1 million [4,5]. RMS commonly presents as a painless tumor
but symptoms such as pain largely depend on the anatomical
location and size of the tumor. Patients with metastatic disease at
(stage 4 of TNM Classification of Malignant Tumors [1]) diagnosis
have a relatively poor prognosis (5-year overall survival of 50% or
lower) with current therapy such as multiagent standard-dose
chemotherapy followed by surgical operation [6].
High-dose chemotherapy (HDCT) has been evaluated as an
alternative treatment option for patients with metastatic RMS. The
rationale for HDCT is that escalating doses of HDCT may increase
survival by capturing putatively remnant malignant cells and thus
overcome cell resistance to standard chemotherapy [7]. The
rationale for autologous hematopoietic stem cell transplantation
(HSCT) following HDCT is a planned rescue for HDCT-related
severe hematologic toxicity [7]. This treatment combination has
life-threatening hematologic adverse events such as graft failure,
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such as multi-organ failure [8]. Of a total of 24,168 HSCT patients
that were registered by the European Group for Blood and Marrow
Transplantation (EBMT) in 2005, 15,278 were autologous HSCT
patients and 69 were indicated for STS [9]. The potential benefit of
this treatment option has not been investigated sufficiently in
controlled studies [10]. Some authors have warned against the use
of HDCT with autologous HSCT, indicating the possibility of
repositioning of malignant cells [11]; others have questioned the
rationale of HDCT with reference to the potential existence of
refractory cancer stem cells [7,12,13].
The question has not been answered whether HDCT followed
by autologous HSCT is able to increase overall survival in patients
with RMS when compared to standard-dose chemotherapy
without HSCT. Since HDCT followed by HSCT is generally
not considered a treatment option for localized tumors, we
concentrated on patients with metastatic RMS. The primary
objective of the present systematic review is to investigate the
overall survival of those patients and the secondary objective was
to assess serious adverse events such as treatment-related mortality
in randomized and non-randomized clinical intervention studies.
Methods
During preparation of this article we adhered to the principles
and checklist of the PRISMA statement [14,15].
Study inclusion criteria
We included patients with metastatic RMS who received
HDCT followed by autologous HSCT. Study design for
comparative effectiveness research was limited to randomized
controlled trials (RCTs) and non-randomized intervention studies
[16]. We did not set a minimum number of patients (sample size)
to be considered. However, we required the proportion of relevant
patients to be at least 80% per study population if no stratification
had been performed. If the proportion of relevant patients was less
than 80% and the results were not presented separately for
patients with other diseases and other inventions, then we
excluded the studies. Study design for a supplemental presentation
of individual data included controlled studies if aggregate data on
overall survival were not reported as well as case series and case
reports. Full-text publications in English language were considered.
We set no limits on year of publication or year of treatment.
Search strategy
MEDLINE (1950 to 2010), EMBASE (1980 to 2010), and The
Cochrane Library (to 2010) were searched without restrictions on
study design, publication year, and language. The first database
search was conducted 05 March 2007. An update search 05
February 2010 included a modified strategy to consider MeSH
changes and exclude animal studies more precisely. We extended
the search strategy by adding the term high-dose chemotherapy
because the term TRANSPLANTATION was not present in title,
abstract, and MeSH terms of some articles even though
transplantation can be considered as their main topic. The MeSH
term BONE MARROW TRANSPLANTATION was deleted
from one category [17]. For 2008 MeSH there was a major
revision of Publication Types (PT) and the phrase "as Topic" was
added [18]. We introduced (ANIMALS not (ANIMALS and
HUMANS)).sh. and replaced (ANIMALS not HUMANS).sh. To
account for these changes, both searches were not restricted to
publication year. The terms and the syntax used for the search
in MEDLINE via Ovid as shown in Table S1 were tailored to
the requirements of the other 2 databases. A final search was
conducted 06 June 2010 in PubMed using MeSH Terms
SARCOMA, STEM CELL TRANSPLANTATION and BONE
MARROW TRANSPLANTATION, and Text Words high dose
chemotherapy as search terms in various combinations. Reference
lists of all included original articles and of 4 recent reviews (Banna
2007 [7]; Ek 2006 [19]; Pedrazzoli 2006 [10]; Verma 2008 [20])
were hand-searched. Information on studies registered at Clin-
icalTrials.gov [21], International Standard Randomised Con-
trolled Trial Number (ISRCTN) Register [22], National Institute
for Health Research UK Clinical Research Network’s (NIHR
UKCRN) Portfolio Database [23], National Cancer Institute
Physician Data Query (NCI PDQ) Clinical Trials [24], European
Group for Blood and Marrow Transplantation (EBMT) Solid
Tumor Working Party (STWP) [25] were searched online (06 June
2010) using the search terms sarcoma, stem cell, transplantation,
and high dose chemotherapy in various combinations.
Study selection
To be included in the present systematic review, we required the
proportion of patients with metastatic RMS as well as the
proportion of patients with HDCT followed by autologous HSCT
to be at least 80% per study population. In the first step, articles
were excluded if the title and/or the abstract clearly referred to
other diagnoses than STS and as well clearly referred to other
interventions than autologous HSCT. In the second step, articles
not excluded in the first step were checked whether patients with
metastatic RMS were evaluated. In the third step, studies
reporting about patients with metastatic RMS were categorized
as controlled trials and as single-arm studies. Reporting of
extractable information about overall survival was required for
all included studies. For each excluded study, an appropriate
reason was documented (Figure 1). All steps of the literature
screening process were performed by two independent reviewers.
Any disagreements were resolved by discussion.
Meta-analysis
The primary effect measure for meta-analysis of controlled
studies was the hazard ratio. In case the hazard ratio was not
directly given in the publication, we extracted summary statistics
from Kaplan Meier product-limit estimations and estimated
hazard ratios according to methods proposed by Parmar 1998
[26]. For estimation, we applied a tool, which uses p-values of the
appropriate log-rank test comparing the two survival functions of
interest, number of patients analyzed, and number of events in
each arm [27]. If this information was not available, hazard ratios
were deduced from the graphical display of the survival curves, if
possible. Meta-analysis was conducted using the generic variance
approach [28,29] and the random effects model [30]. Calculations
were conducted using SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina, United States). The results of the meta-analysis
were graphically displayed by means of a forest plot. Heteroge-
neity of the results was visually assessed and quantified using the I
2
value [31]. In case of considerable heterogeneity (I
2$50%) a
pooled estimate is not sensible and, therefore, was not calculated
[32].
To summarize outcome from individual data, Kaplan-Meier
survival time estimates were extracted directly from the text or
deduced from the survival curve of the publication. Individual data
were pooled and an estimate for the overall survival was calculated
by means of a time-to-event analysis according to the Kaplan-
Meier product-limit method [33]. Calculations were conducted
using the procedure Lifetest of the SAS version 9.2 (SAS Institute
Inc., Cary, North Carolina, United States). The condition for
including the individual data in this analysis was that information
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follow-up for each patient.
Data collection and analysis
All steps of the data collection process were performed by two
independent reviewers. Any disagreements were resolved by
discussion. We collected study characteristics such as the number
and region of participating centers, the treatment period, the
number of analyzed patients per treatment arm; and the
proportion of patients with conditions other then metastatic
RMS and a regimen other than HDCT followed by autologous
HSCT. Median age and gender were extracted as patients’
characteristics.
The primary outcome was overall survival. Survival estimates
were extracted directly from the text or deduced from the survival
curve of the publication. The principal summary measusure was
the hazard ratio as specified in the meta-analysis section. We
extracted the p-value of the log-rank test of the overall survival
functions and the 3-year estimate of both treatment arms as well as
the number of surviving patients and the median follow-up if
reported.
The secondary outcomes were treatment-related mortality,
secondary neoplasia, toxicity, and health-related quality of life.
Treatment-related mortality was defined as deaths that have been
classified by the individual publication as treatment-related deaths,
or patients that have died of complications. Secondary neoplasia
were considered as classified by the individual publication. HRQOL
was considered if the data were measured using a questionnaire that
had been validated through reporting of norms in a peer-reviewed
publication. Severe adverse events grades 3 to 4 of toxicity [34] were
extracted and grouped as hematological (leukopenia, neutropenia,
thrombocytopenia), and non-hematological (kidney, liver, nervous
system, heart) toxicity.
Risk of bias
Risk of bias within studies was evaluated by assessing study
design, such as retro- or prospective planning, concurrent control
group, criteria for assignment of patients to treatment arms,
control for confounding factors and other criteria, such as unclear
selection of patients and analysis of the same patients in both
treatment groups, that may increase the risk of bias especially in
non-randomized trials [35]. A low risk of bias required a yes for all
three of the following topics: concurrent control group, control for
confounding factors, and no other risk of bias factors.
Risk of bias across studies was evaluated by assessing publication
bias and outcome reporting bias. We evaluated potentially
relevant studies to identify studies that may have been excluded
because of missing or insufficient outcome reporting. We evaluated
published study protocols to identify outcome reporting different
from appropriate procotols.
Results
Search results
Of 4,784 retrieved publications, 467 full-text papers were
obtained for further assessment (Figure 1). A total of 40 studies
(287 transplant patients with metastatic RMS) were included. The
data were structured to distinguish studies with aggregate data
(controlled and non-controlled trials) from studies with individual
data. Only 3 studies [36–38] (108 transplant patients, 104 controls)
had a controlled, yet not randomized study design. Of the
remaining 37 studies, aggregate data were extractable from 2 case
series [39,40] (77 transplant patients) and individual data were
extractable from 35 further case series and case reports [41–75]
(102 transplant patients). We did not identify any RCTs. Two
recently published studies did not meet the inclusion criteria. The
number of transplanted patients and their outcome was not
reported separately in a non-randomized controlled study [76].
The proportion of metastatic patients was 67% of the study
population in a single-arm study [77].
Baseline data
An overview of the main study design and patients’ character-
istics of 3 controlled studies and of 2 non-controlled studies with
aggregate data is presented in Table 1. In studies reporting
aggregate data, transplantations were performed between 1991
and 2003. The studies included children and young adults ranging
from 0 to 32 years of age. The number of individual data of
patients with metastatic RMS included in 35 case series and case
reports as well as the number of data included in a meta-analysis
are shown in Table S2.
All 3 controlled studies and 1 single-arm study reported exclusively
patients with metastatic RMS at diagnosis. In the other single-arm
study, 1 of 7 patients did not have metastatic disease.
Primary outcome
An overview of data on overall survival is presented in Table 2.
In one prospective controlled trial [38], 3-year overall survival for
transplant vs. non-transplant patients was estimated at 22% vs.
55%. The difference between the treatment groups was statistically
significant (log-rank p-value=0.001). In a retrospective question-
naire-based controlled trial, the difference in overall survival
between the treatment groups was also statistically significant but
with reversed direction of effect (hazard ratio 0.38; 95% CI 0.17 to
0.88). The estimated survival after 3 years was 53% vs. 18% for
transplant patients vs. non-transplant patients [37]. The estimates
of another controlled trial [36] showed a numerical tendency in
favor of HDCT followed by autologous HSCT (40% vs. 28%, log-
rank p-value=0.2), but the difference between the results of the
treatment groups was statistically not significant.
We conducted a meta-analysis for overall survival of the
3 controlled trials based on hazard ratio and visualized
the contradicting results in a forest plot (Figure 2). Considerable
statistical heterogeneity (I
2=85%) between the controlled studies
did not justify the presentation of a pooled estimate. In Hosoi 2007
[37] patients with metastatic embryonal RMS who were younger
than 10 years of age were excluded from the analysis. The number
of excluded patients was not reported and constituted probably a
small fraction. We did not identify statistically significantly
different characteristics such as bone marrow metastasis between
the treatment groups within one trial and across all 3 controlled
trials.
Figure 1. Literature search and study flow. Studies: Bader 1989 [106]; Bisogno 2009 [39]; Carli 1999 [36]; Carli 2004 [107]; Dumontet 1992 [93];
Hosoi 2007 [37]; Klingebiel 2008 [38]; Koscielniak 1997 [108]; Matsubara 2003 [109]; Suita 2005 [110]; Yamada 2007 [40]. Abbreviations. Literature
search and study flow. Abbreviations: EBMT STWP: European Group for Blood and Marrow Transplantation Soft Tissue Working Party; HDCT: high-
dose chemotherapy; HSCT: hematopoietic stem cell transplantation; N: number; NCI PDQ: National Cancer Institute Physician Data Query Clinical
Trials; NIHR UKCRN: National Institute for Health Research (NIHR) UK Clinical Research Network’s Portfolio Database; NRSTS: non-rhabdomyosarcoma
soft tissue sarcoma; RMS: rhabdomyosarcoma; STS: soft tissue sarcoma.
doi:10.1371/journal.pone.0017127.g001
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autologous HSCT reported in 2 single-arm studies with aggregate
data were at 28% [40] and at 42% [39]. These estimates were
within the range for this treatment option (22% to 53%), which
was reported in the 3 controlled trials. We conducted a meta-
analysis of the pooled individual outcome data (Table 2). The
Kaplan-Meier product-limit estimation resulted in a pooled
estimate 3 years after treatment at 29% (95% CI: 15 to 43)
(Figure 3). Again, this value was within the range of the 3
controlled trials. It should be noted that only 45% (45 out of 101
patients) of all included individual data were suitable for this
analysis.
Secondary outcomes
Extractable data on treatment-related mortality were reported
for 10 transplant patients in 8 studies (Table 3) and secondary
neoplasia for 1 transplant patients in 1 study (Table 3). There was
a lack of extractable data on severe (grade 3 to 4) non-
hematological toxicity in a large proportion of the included
studies. Two patients with kidney and 1 patient with heart toxicity
were reported. In 3 studies, liver toxicity was not present in all
evaluated patients (Table 3). Due to the low quantity of analyzable
data, it was not possible to reasonably evalute toxicity. A study on
health-related quality of life [78] could not be included in the
benefit assessment because the results were not connected to each
individual diagnosis but rather reported for a group of transplant-
ed patients with various diseases. We did not identify any studies
with health-related quality of life endpoints.
Risk of bias
Risk of bias within studies was high for all included studies
mainly due to flaws of study design, assignment of patients to
treatment groups, and missing control for confounding (Table 4).
Due to historical controls in the study design used in the study of
Carli 1999 [36], patients in the control group were recruited
earlier in time than patients who received HDCT followed by
autologous HSCT. This allocation to treatment groups by time
differences may introduce selection bias [79]. Only data of 96
Table 1. Study and patient’s characteristics.
Study N. centers/country Treatment period; years
N. evaluable
patients
*
Metastatic
RMS; %
Age; median
years (range)
Gender;
% males
Non-randomized controlled studies
Carli 1999/2004 [36,107] 5/Europe HSCT 1991 to 1995 vs. (historical)
control 1989 to 1991
52 vs. 44 100 vs. 100 (0 to 18) –
Hosoi 2007 [37] 63/Japan 1991 to 2002 22 vs. 20 100 vs. 100 (0 to 20) –
Klingebiel 2008 [38] 50
{/Europe 1995 to 2003 34 vs. 40 100 vs. 100 (under 22) –
Single-arm studies with aggregate data
Bisogno 2009 [39] 1/Italy – 70
{ 100 (0 to 20) 47
Yamada 2007 [40] 1/Japan – 7 86 (6/7) (15 to 32) 29
– information not reported in the publication or not applicable.
*for non-randomized controlled studies: HSCT vs. control.
{Klingebiel 2008: 295 patients were registered at 88 centers; 96 patients from 50 centers were analyzed in the study.
{Bisogno 2009: 11% patients (8 of 70 patients) without HSCT included.
Abbreviation. HSCT: hematopoietic stem cell transplantation; RMS: rhabdomyosarcoma.
doi:10.1371/journal.pone.0017127.t001
Table 2. Overall survival.
Study
Follow-up
begins at
3-year overall survival
(95% CI if reported), HSCT vs. control; %
Statistically significant
difference
Non-randomized controlled studies
Carli 1999/Carli 2004
* [36,107] diagnosis 40 (26 to 55) vs. 28 (13 to 42)
{ no (p=0.200)
{
Hosoi 2007 [37] diagnosis 53 vs. 18
1 YES (0.38 (0.17 to 0.88))
||
Klingebiel 2008 [38] diagnosis 22 vs. 55
1 YES (p=0.001)
{
Single-arm studies with aggregate data
Bisogno 2009 [39] diagnosis 42 (31 to 54) not applicable
Yamada 2007 [40] treatment 28 not applicable
Pooled individual data
45 patients (19 studies) treatment 29 (15 to 43) not applicable
*Carli 2004 follow-up paper of Carli 1999.
{Carli 2004: 5-year overall survival for HSCT 36% (95% CI 23% to 49%) vs. control 27% (95% CI 14% to 41%).
{p-value of log-rank test.
1Hosoi 2007 and Klingebiel 2008: 3-year survival estimates deduced from the graphical display of the survival curves.
||hazard ratio (95% confidence interval).
Abbreviation. CI: conficence interval; HSCT: hematopoietic stem cell transplantation; RMS: rhabdomyosarcoma.
doi:10.1371/journal.pone.0017127.t002
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because complete remission before the third chemotherapy cycle
was required for inclusion. Consequently, data of 78 patients were
not considered because they did not achieve the required complete
remission. Data of one patient were excluded because therapy
information was missing.
Klingebiel 2008 [38] analyzed 96 (33%) of 295 enrolled
metastasizing patients with soft tissue sarcoma in a prospective
multicenter trial. Data of 37 patients were not included because of
missing treatment information, data of 162 patients were not
included because of incomplete treatment. The proportion of
RMS patients among 199 enrolled but not analyzed patients was
not reported. Of 96 analyzed patients, 22 patients had a diagnosis
other than RMS and the rest of 74 patients with metastatic RMS
were investigated in a subgroup analysis. Patients in the control
group were treated with an oral maintenance treatment, which may
not be a typical example of conventional chemotherapy and
the outcome may not be comparable with those of other studies.
In contrast to the overall study result, in a subgroup analysis of
43 RMS patients with bone and/or bone marrow involvement
the overall survival was not different between test and control
group.
Hosoi 2007 [37] defined a high-risk group of 42 (13%)
metastasizing RMS patients (TNM IV) of a total of 331 enrolled
patients with RMS. These data were collected from 63 institutions
after a questionnaire had been sent to 93 institutions. A non-
responder analysis was not reported. Selection bias may be
considerable due to a questionnaire-based analysis. Patients with
metastasizing embryonal RMS who were younger than 10 years of
age were analyzed in another risk group. Exclusion of these
patients from the high-risk group may have influenced the outcome
and reduced its comparability with those of other studies.
Figure 2. Meta-analysis of overall survival of 3 controlled studies. A meta-analysis of overall survival of 3 controlled trials based on hazard
ratio was conducted. The forest plot shows conflicting results between these trials. Condiderable heterogeneity did not justify a pooled estimate.
doi:10.1371/journal.pone.0017127.g002
Figure 3. Meta-analysis of pooled individual data of single arm studies. Kaplan-Meier product-limit estimation of overall survival was
conducted using individual data of patients with metastatic RMS (total 45, failed 31, censored 14) from 19 case series and case reports. Information
about outcome (dead or alive) and follow-up (time of survival after begin of treatment) was required for each individual. A considerable proportion of
56% (57/102 patients) of all included individual data was not considered because appropriate information was not extractable. Number of subjects at
risk after each additional year of follow-up.
doi:10.1371/journal.pone.0017127.g003
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number of trials included in the meta-analysis was too small for
conducting a funnel plot. We did not identify significant outcome
reporting bias.
Discussion
Primary outcome
We conducted a meta-analysis based on hazard ratios of overall
survival and found conflicting results in 3 controlled trials. A
pooled estimate was not presented because statistical heterogeneity
can be categorized as considerable [80]. Heterogeneity was not
explained by the distribution of clinical characteristics between
treatment groups. Outcome data varied considerably between
studies and the 3-year overall survival estimates after HDCT
followed by autologous HSCT ranged from 22% to 52% in the 3
controlled trials. Results from single-arm studies based on
aggregate data or on pooled individual data were within this
range.
To our knowledge, this is the first systematic review and meta-
analysis that compares HDCT followed by autologous HSCT vs.
standard-dose chemotherapy without transplantation in patients
Table 3. Adverse events in HSCT group of all included studies.
Study
N. affected/N.
evaluated patients Specification
Treatment-related mortality
Bisogno 2009 [39] 3/70 2x sepsis, 1x capillary leak syndrome
Carli 1999
* [36,107] 1/52 Sepsis
Chan 1991 [44] 1/1 Renal failure, acute respiratory distress syndrome, and aluminium cardiomyopathy
Ekert 1984 [45] 1/2 Sepsis
Hara 1998 [51] 1/3 Renal tubular acidosis
Hawkins 2002 [52] 1/6 Acute respiratory distress syndrome
Kwon 2010 [59] 1/3 Sepsis with multiorgan failure and major bleeding
Sanz 1997 [72] 1/1 Acute renal failure
Secondary neoplasia
Yamada 2007 [40] 1/7 Myelodysplastic syndrome
Non-hematological toxicity
Carli 1999 [36,107] 0/30 Liver toxicity
Hara 1998 [51] 2/7 Kidney toxicity
Lucidarme 1998 [62] 0/5 Liver as well as kidney toxicity
Williams 2004 [75] 0/4 Liver as well as kidney toxicity
Williams 2004 [75] 1/4 Heart toxicity
*Carli 1999: in addition, 1 TRM was reported for the control group (anthracycline-related cardiotoxicity); in the follow-up paper Carli 2004, a total of 6 TRM were
reported. However, the assignment to the treatment groups was not clear.
{National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade III to IV.
Abbreviation. HSCT: hematopoietic stem cell transplantation.
doi:10.1371/journal.pone.0017127.t003
Table 4. Risk of bias.
Included studies
Prospective
design
Concurrent
control
Assignment criteria
reported
Control for
confounding
factors
*
No other risk
of bias factors
{
Risk of
bias
{
Non-randomized controlled studies
Carli 1999/2004 [36,107] YES no no no no high
Hosoi 2007 [37] no
1 YES no no no high
Klingebiel 2008 [38] YES YES no no
|| no high
– information not reported in the publication or not applicable.
*Control for confounding factors; no: no adjusted analysis.
{No other risk of bias factors; no: selection of patients unclear; except Gluckman 1979: no: 5 patients with failed first-line IST followed by second-line HSCT were
analyzed in both treatment groups.
{Risk of bias: LOW required concurrent control group (YES), control for confounding factors (YES), and no other risk of bias factors (YES).
1Hosoi 2007: questionnaire sent to hospitals.
||Klingebiel 2008: The heading of table III of the paper indicates that RMS and RMS-like patients (n=74+14=88) were assessed in the multivariate analysis. According to
the text, patients of interest with RMS only (n=74) were analyzed. The author confirmed the former statement that RMS and RMS-like patients (n=88 patients) were
analyzed (personal communication).
doi:10.1371/journal.pone.0017127.t004
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single-arm studies on HDCT followed by autologous HSCT in
patients with metastatic and relapsed RMS. Verma 2008 [20]
investigated HDCT followed by autologous HSCT in patients
with inoperable, locally advanced, or metastatic STS, reported the
results of 2 single-arm studies on STS, and did not address
specifically data on RMS. Admiraal 2007 [82] conducted a
systematic review exclusively on patients with metastatic RMS.
Secondary outcome
Treatment-related mortality was extractable from only few
studies. Early (,100 days) and late mortality ($100 days) was not
differentiated in the studies. Secondary neoplasia was extractable
from one study. Similarly, non-hematological toxicity was
extractable only from a few studies. As events are expected to
cumulate with time, the incidence rate of secondary neoplasia in
the present systematic review may be underestimated because of a
short follow-up time and of loss of patients to follow-up.
Treatment-related mortality, secondary neoplasia, and toxicity
proportion was not summarized due to scarcity of data.
Outcome reporting bias
Outcome reporting bias [83] is defined as the selection of a
subset of the original recorded outcome variables for publication.
Systematic reviews require addressing the issue of missing outcome
data because outcome reporting bias can affect their conclusions
[84].
We did not identify significant outcome reporting bias. All 3
controlled trials reported statistical summary data such as hazard
ratio and p-values of log-rank test. Incomplete data as well as a
short follow-up may have compromised the results.
Study publication bias
Study publication bias is defined as publication of research
results depending on their results [85]. The number of trials
included in the meta-analysis was too small for conducting a
funnel plot analysis because at least 10 trials are required for a
reasonable analysis [86]. The strengths of the present systematic
review are the broadness of the search strategy and the
comprehensiveness of the published data included. Nevertheless,
there may be a slight possibility that an unknown number of
studies were not registered and not published.
Language bias
Results in English language articles could be different from
those of articles written in another language [87]. Non-English
language requires expensive translation to prevent selective
outcome extraction and misinterpretation of results. Funding for
translation was not provided and we excluded all non-English
including German language articles. Restricting the inclusion of
studies to English language may have little effect on summary
treatment effect estimates [88,89] and German language articles
may not play a preeminent role in the dissemination of medical
research [90].
Internal validity
We identified a high risk of bias within all studies. The criteria of
allocation of the patients to the treatment groups were not
reported in all included studies. Klingebiel 2008 [38] reported the
outcome of interest in a subgroup analysis but did not present
baseline data for this subgoup. Hosoi 2007 [37] and Carli 1999
[36] did not report median age and distribution of gender. The
contradictory results reported by Klingebiel 2008 [38] vs. Hosoi
2007 [37] call for an explanation. Both authors reported patients
with metastatic RMS in a subgroup. Hosoi 2007 [37] excluded
patients with metaststic embryonal RMS younger than 10 years of
age but Klingebiel 2008 [38] did not. Baseline data for the
subgroup were not sufficient to specify the number of excluded
patients. The 2 studies (Klingebiel 2008 [38] vs. Hosoi 2007 [37])
had a different setting (Germany vs. Japan), a different design
(prospective vs. retrospective), and a different data collection
process (protocol driven clinical trial vs. questionnaire). We did not
find any statistically significant differences of the patients’
characteristics between the treatment groups.Given the data
presented, it remains a matter of speculation whether the risk of
bias within the studies might explain the different outcome as we
do not know in what direction the results were possibly biased.
Heterogeneity
Strict adherence to inclusion criteria limited clinical heteroge-
neity to a low to moderate range. Patient’s characteristics such as
clinical stage, age, and histological subtypes were roughly
comparable between the treatment groups.
Lack of controlled trials
For sarcomas, at least 20 articles [8,11,19,54,81,91–105]
addressed the need for conducting RCTs to evaluate the role of
HDCT followed by autologous HSCT vs. standard-dose chemo-
therapy. Consequently, the lack of RCTs and the lack of clinical
controlled trials addressing the issue is suprising indeed. Only 3
non-randomized controlled studies of poor quality were published
to date and are included in the present review. According to the
European Group for Blood and Marrow Transplantation (EBMT),6 9
autologous HSCT were assigned to patients with soft tissue
sarcoma in the year 2005 [9].
Conclusions
High-dose chemotherapy followed by autologous hematopoietic
stem cell transplantation in patients with metastatic rhabdomyo-
sarmoa remains an experimental treatment. At present, it does not
appear justifiable to use this treatment except in appropriately
designed controlled trials.
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